Mapracorat

Generic Name
Mapracorat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C25H26F4N2O2
CAS Number
887375-26-0
Unique Ingredient Identifier
145V79YBVP
Background

Mapracorat has been investigated for the treatment of Eczema and Atopic Dermatitis.

Associated Conditions
-
Associated Therapies
-

Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-11-29
Last Posted Date
2013-11-26
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
61
Registration Number
NCT01736462
Locations
🇺🇸

Bausch & Lomb Inc, Rochester, New York, United States

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3
Completed
Conditions
Interventions
First Posted Date
2012-05-04
Last Posted Date
2020-09-03
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
360
Registration Number
NCT01591655
Locations
🇺🇸

Bausch & Lomb, Incorporated, Rochester, New York, United States

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3
Completed
Conditions
Interventions
First Posted Date
2012-05-03
Last Posted Date
2020-09-03
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
369
Registration Number
NCT01591161
Locations
🇺🇸

Bausch & Lomb Incorporated, Rochester, New York, United States

HPA Axis Study in Adults

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-08-03
Last Posted Date
2023-10-31
Lead Sponsor
Bayer
Target Recruit Count
23
Registration Number
NCT01408511
Locations
🇿🇦

PAREXEL Port Elizabeth, Port Elizabeth, South Africa

🇿🇦

PAREXEL Bloemfontein, Bloemfontein, South Africa

🇿🇦

PAREXEL George, George, South Africa

HPA Axis Study in Japanese Adults

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-08-02
Last Posted Date
2023-09-21
Lead Sponsor
Bayer
Target Recruit Count
12
Registration Number
NCT01407510
Locations
🇯🇵

Clinical Research Hospital Tokyo, Tokyo, Japan

🇯🇵

Kawaguchi Kogyo General Hospital, Saitama, Japan

🇯🇵

Tokyo Women's Medical University, Tokyo, Japan

Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)

First Posted Date
2011-05-25
Last Posted Date
2015-01-21
Lead Sponsor
Bayer
Target Recruit Count
197
Registration Number
NCT01359787

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2011-02-18
Last Posted Date
2020-09-03
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
177
Registration Number
NCT01298752
Locations
🇺🇸

Bausch & Lomb Incorporated, Rochester, New York, United States

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-02-03
Last Posted Date
2020-09-04
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
236
Registration Number
NCT01289431
Locations
🇺🇸

Bausch & Lomb, Rochester, New York, United States

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-10-28
Last Posted Date
2020-09-03
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
311
Registration Number
NCT01230125
Locations
🇺🇸

Bausch & Lomb, Incorporated, Rochester, New York, United States

© Copyright 2024. All Rights Reserved by MedPath